Suppr超能文献

通过下一代测序发现幽门螺杆菌对克拉霉素耐药的新突变

Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing.

作者信息

Binh Tran Thanh, Shiota Seiji, Suzuki Rumiko, Matsuda Miyuki, Trang Tran Thi Huyen, Kwon Dong Hyeon, Iwatani Shun, Yamaoka Yoshio

机构信息

Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Oita, Japan Department of Endoscopy, Cho Ray Hospital, Ho Chi Minh, Vietnam.

Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Oita, Japan.

出版信息

J Antimicrob Chemother. 2014 Jul;69(7):1796-803. doi: 10.1093/jac/dku050. Epub 2014 Mar 19.

Abstract

OBJECTIVES

Resistance to clarithromycin is the most important factor causing failure of Helicobacter pylori eradication. Although clarithromycin resistance is mainly associated with three point mutations in the 23S rRNA genes, it is unclear whether other mutations are associated with this resistance.

METHODS

Two types of clarithromycin-resistant strains (low- and high-resistance strains) were obtained from clarithromycin-susceptible H. pylori following exposure to low clarithromycin concentrations. The genome sequences were determined with a next-generation sequencer. Natural transformation was used to introduce the candidate mutations into strain 26695. Etest and an agar dilution method were used to determine the MICs.

RESULTS

High-resistance strains contained the mutation A2143G in the 23S rRNA genes, whereas low-resistance strains did not. There were seven candidate mutations in six genes outside of the 23S rRNA genes. The mutated sequences in hp1048 (infB), hp1314 (rpl22) and the 23S rRNA gene were successfully transformed into strain 26695 and the transformants showed an increased MIC of and low resistance to clarithromycin. The transformants containing a single mutation in infB or rpl22 (either a 9 bp insertion or a 3 bp deletion) or the 23S rRNA gene showed low MICs (0.5, 2.0, 4.0 and 32 mg/L, respectively) while the transformants containing double mutations (mutation in the 23S rRNA genes and mutation in infB or rpl22) showed higher MICs (>256 mg/L).

CONCLUSIONS

Next-generation sequencing can be a useful tool for screening mutations related to drug resistance. We discovered novel mutations related to clarithromycin resistance in H. pylori (infB and rpl22), which have synergic effects with 23S rRNA resulting in higher MICs.

摘要

目的

对克拉霉素耐药是导致幽门螺杆菌根除失败的最重要因素。尽管克拉霉素耐药主要与23S rRNA基因中的三个点突变相关,但尚不清楚其他突变是否与这种耐药性有关。

方法

在低浓度克拉霉素作用下,从对克拉霉素敏感的幽门螺杆菌中获得两种类型的克拉霉素耐药菌株(低耐药和高耐药菌株)。用新一代测序仪测定基因组序列。采用自然转化法将候选突变导入26695菌株。采用Etest和琼脂稀释法测定最低抑菌浓度(MIC)。

结果

高耐药菌株在23S rRNA基因中含有A2143G突变,而低耐药菌株则没有。在23S rRNA基因以外的六个基因中有七个候选突变。hp1048(infB)、hp1314(rpl22)和23S rRNA基因中的突变序列成功转化到26695菌株中,转化子对克拉霉素的MIC增加且表现出低耐药性。在infB或rpl22(9 bp插入或3 bp缺失)或23S rRNA基因中含有单个突变的转化子显示出低MIC(分别为0.5、2.0、4.0和32 mg/L),而含有双突变(23S rRNA基因中的突变和infB或rpl22中的突变)的转化子显示出更高的MIC(>256 mg/L)。

结论

新一代测序可作为筛选与耐药相关突变的有用工具。我们在幽门螺杆菌中发现了与克拉霉素耐药相关的新突变(infB和rpl22),它们与23S rRNA具有协同作用,导致更高的MIC。

相似文献

1
Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing.
J Antimicrob Chemother. 2014 Jul;69(7):1796-803. doi: 10.1093/jac/dku050. Epub 2014 Mar 19.
4
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
BMC Microbiol. 2016 Nov 4;16(1):256. doi: 10.1186/s12866-016-0873-6.
8
Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.
J Microbiol. 2013 Aug;51(4):448-52. doi: 10.1007/s12275-013-2465-6. Epub 2013 Aug 30.

引用本文的文献

1
Types of 23S Ribosomal RNA Point Mutations Affecting Eradication Rates in Clarithromycin-Based Triple Therapy.
Korean J Helicobacter Up Gastrointest Res. 2023 Dec;23(4):268-276. doi: 10.7704/kjhugr.2023.0037. Epub 2023 Dec 8.
2
Targeted nanomedicines for the treatment of infection.
Mater Today Bio. 2025 Apr 30;32:101820. doi: 10.1016/j.mtbio.2025.101820. eCollection 2025 Jun.
5
Exploring the Molecular Mechanisms of Macrolide Resistance in Laboratory Mutant .
Antibiotics (Basel). 2024 Apr 26;13(5):396. doi: 10.3390/antibiotics13050396.
6
Antibiotic Resistance of : Mechanisms and Clinical Implications.
J Korean Med Sci. 2024 Jan 29;39(4):e44. doi: 10.3346/jkms.2024.39.e44.
7
Testing for in an era of antimicrobial resistance.
J Clin Microbiol. 2024 Feb 14;62(2):e0073223. doi: 10.1128/jcm.00732-23. Epub 2024 Jan 9.
9
Antibiotic Resistance, Susceptibility Testing and Stewardship in Infection.
Int J Mol Sci. 2023 Jul 20;24(14):11708. doi: 10.3390/ijms241411708.
10
Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.
J Clin Lab Anal. 2023 Apr;37(7):e24885. doi: 10.1002/jcla.24885. Epub 2023 Apr 23.

本文引用的文献

2
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.
Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.
3
Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.
World J Gastrointest Pathophysiol. 2011 Jun 15;2(3):35-41. doi: 10.4291/wjgp.v2.i3.35.
4
Guidelines for treatment of Helicobacter pylori in the East and West.
Expert Rev Anti Infect Ther. 2011 Aug;9(8):581-8. doi: 10.1586/eri.11.80.
7
New implications on genomic adaptation derived from the Helicobacter pylori genome comparison.
PLoS One. 2011 Feb 28;6(2):e17300. doi: 10.1371/journal.pone.0017300.
8
H. pylori DNA Transformation by Natural Competence and Electroporation.
Methods Mol Med. 1997;8:145-52. doi: 10.1385/0-89603-381-3:145.
9
Worldwide H. pylori antibiotic resistance: a systematic review.
J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14.
10
Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up.
Dig Liver Dis. 2011 Apr;43(4):295-9. doi: 10.1016/j.dld.2010.10.012. Epub 2010 Nov 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验